查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587286

大腸直腸癌藥物市場：按藥物類別、治療類型、給藥途徑、分銷管道分類 - 全球預測 2025-2030

Colorectal Cancer Drugs Market by Drug Class, Treatment Type, Route of Administration, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年大腸直腸癌治療市值為108.2億美元，預計2024年將達到113.6億美元，複合年成長率為5.12%，到2030年將達到153.6億美元。

大腸直腸癌治療市場包括針對大腸直腸癌（一種影響結腸和直腸的常見癌症）的治療藥物的研究、開發、製造和商業化。此細分市場包括多種產品，包括化療、免疫療法、標靶治療和旨在增強治療效果的小分子化合物。對大腸直腸癌藥物的需求是由於這種疾病的高盛行率，開發有效的治療方法以改善患者的預後和存活率至關重要。這些藥物主要由腫瘤科醫生、外科醫生和專門從事腫瘤學的醫療機構在醫院、專科診所和研究機構使用。大腸直腸癌發生率上升、人口老化、醫療保健支出增加以及生物技術和分子診斷的進步是關鍵的成長動力，為製藥公司創造了擴張機會。然而，嚴格的監管流程、高昂的治療成本和潛在的副作用是市場成長的主要障礙。此外，來自生物相似藥和學名藥的競爭給藥品價格帶來壓力並限制了利潤率。個人化醫療、新型藥物傳遞系統和聯合治療等領域的創新對於對抗抗藥性和改善患者治療效果至關重要。公司應投資於研發並考慮研究合作以促進創新。透過擴大新興地區的准入範圍，該市場顯示出成長潛力，這些地區的意識提高和醫療基礎設施的改善加速了藥物的採用。此外，基因組學和蛋白​​質組學的技術進步為針對個別患者概況的個人化大腸癌治療提供了機會。市場相關人員必須專注於加強供應鏈、最佳化定價策略、有效利用監管途徑。總體而言，這個市場的動態性質要求能夠靈活地應對技術進步和醫療保健政策的變化，為尋求創新和應對市場挑戰的公司創造充滿活力的業務，這表明存在機會。

主要市場統計
基準年[2023] 108.2億美元
預測年份 [2024] 113.6億美元
預測年份 [2030] 153.6億美元
複合年成長率（%） 5.12%

市場動態：快速發展的結直腸癌藥物市場的關鍵市場洞察

供需的動態交互作用正在改變大腸直腸癌藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 全球大腸直腸癌發生率迅速增加
    • 增加抗癌藥物研發的投資和政府資助
    • 新藥快速傳播
  • 市場限制因素
    • 開發結腸癌藥物成本高昂
  • 市場機會
    • 增加大腸直腸癌治療的研究和開發
    • 網路藥局和遠端醫療設施的普及
  • 市場挑戰
    • 用於高風險大腸直腸癌治療的新輔助/輔助管道藥物開發不足

波特五力：駕馭大腸直腸癌藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對大腸直腸癌藥物市場的影響

外部宏觀環境因素對大腸直腸癌治療藥物市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解大腸直腸癌治療藥物市場的競爭狀況

對大腸直腸癌治療藥物市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV 大腸直腸癌治療市場定位矩陣供應商績效評估

FPNV定位矩陣是評估大腸直腸癌治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪結直腸癌治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，結直腸癌治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 大腸直腸癌和直腸癌的發生率在世界各地迅速增加。
      • 增加對癌症藥物開發的投資和政府資助
      • 新藥快速引進
    • 抑制因素
      • 開發治療大腸直腸癌的藥物需要花費大量資金
    • 機會
      • 增加大腸直腸癌治療的研發
      • 線上藥局和遠端醫療設施的激增
    • 任務
      • 缺乏用於治療高風險大腸直腸癌的新藥和術後輔助管線藥物的開發
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 依藥物類別分類的大腸直腸癌治療藥物市場

  • 抗血管新生藥物
  • 化療藥物
  • 免疫治療藥物
  • 標靶治療

第7章依治療類型分類的大腸直腸癌治療藥物市場

  • 一線治療
  • 二線治療
  • 三線及以上治療

第8章大腸直腸癌治療藥物市場：依給藥途徑

  • 靜脈
  • 口服
  • 皮下的

第9章大腸直腸癌治療藥物市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章 北美和南美大腸直腸癌藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區大腸直腸癌治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲大腸直腸癌治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 武田獲得結直腸癌潛在治療方法的批准
    • FDA加速核准圖卡替尼合併曲妥珠單抗治療大腸直腸癌
    • Carina Biotech 為大腸癌研究籌集資金
  • 戰略分析和建議

公司名單

  • Accord Healthcare Limited by Intas Pharmaceuticals Ltd.
  • Amgen Inc.
  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • HUTCHMED（China）Limited
  • Lupin Limited
  • Mallinckrodt Pharmaceuticals
  • Manus Aktteva Biopharma LLP
  • Marksans Pharma Ltd.
  • Merck & Co., Inc.
  • Mylan NV by Viatris Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Sumitomo Pharma Co., Ltd.
  • Taiho Pharmaceutical Co., Ltd. by Otsuka Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • VolitionRx Limited
Product Code: MRR-431B7BFFBF56

The Colorectal Cancer Drugs Market was valued at USD 10.82 billion in 2023, expected to reach USD 11.36 billion in 2024, and is projected to grow at a CAGR of 5.12%, to USD 15.36 billion by 2030.

The colorectal cancer drugs market encompasses the research, development, manufacturing, and commercialization of therapeutic drugs targeting colorectal cancer, a common cancer affecting the colon and rectum. This market segment includes a range of products such as chemotherapy, immunotherapy, targeted therapy, and small molecules designed to enhance treatment outcomes. The necessity for colorectal cancer drugs arises from the high prevalence of the disease, making it critical to develop effective treatments that improve patient prognosis and survival rates. These drugs find application within hospitals, specialty clinics, and research institutes, and are primarily used by oncologists, surgeons, and healthcare institutions focused on oncology. The rising incidence of colorectal cancer, coupled with an aging population, increasing healthcare expenditure, and advancements in biotechnology and molecular diagnostics, serve as key growth drivers, creating expansion opportunities for pharmaceutical companies. However, stringent regulatory processes, high treatment costs, and potential side effects pose significant barriers to market growth. Additionally, competition from biosimilars and generic drugs pressures drug pricing and limits profit margins. Innovation is essential in areas like personalized medicine, novel drug delivery systems, and combination therapies to address drug resistance and improve patient outcomes. Companies should invest in R&D and consider collaborations to expedite innovation. The market shows potential for growth through expanded access in emerging regions, where increasing awareness and better healthcare infrastructure can accelerate drug uptake. Additionally, technological advancements in genomics and proteomics present opportunities for personalized colorectal cancer drugs tailored to individual patient profiles. To thrive, market players must focus on bolstering supply chains, optimizing pricing strategies, and navigating regulatory pathways efficiently. Overall, the dynamic nature of this market requires agility in responding to technological advancements and shifts in healthcare policies, indicating vibrant opportunities for companies dedicated to innovating and addressing market challenges.

KEY MARKET STATISTICS
Base Year [2023] USD 10.82 billion
Estimated Year [2024] USD 11.36 billion
Forecast Year [2030] USD 15.36 billion
CAGR (%) 5.12%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Colorectal Cancer Drugs Market

The Colorectal Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Surging prevalence of colon and rectal cancer worldwide
    • Increase in investments and government funding in development of cancer drugs
    • Rapid adoption of novel medicines
  • Market Restraints
    • High cost for developing colon cancer drugs
  • Market Opportunities
    • Increasing research and development studies for colorectal cancer treatment
    • Proliferation of online pharmacies and telehealth facilities
  • Market Challenges
    • Lack of development in the neoadjuvant/adjuvant pipeline agents for the treatment of high risk colorectal cancer

Porter's Five Forces: A Strategic Tool for Navigating the Colorectal Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Colorectal Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Colorectal Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Colorectal Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Colorectal Cancer Drugs Market

A detailed market share analysis in the Colorectal Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Colorectal Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Colorectal Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Colorectal Cancer Drugs Market

A strategic analysis of the Colorectal Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Colorectal Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include Accord Healthcare Limited by Intas Pharmaceuticals Ltd., Amgen Inc., Amneal Pharmaceuticals, Inc., Apotex Inc., Bayer AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, HUTCHMED (China) Limited, Lupin Limited, Mallinckrodt Pharmaceuticals, Manus Aktteva Biopharma LLP, Marksans Pharma Ltd., Merck & Co., Inc., Mylan N.V. by Viatris Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Sumitomo Pharma Co., Ltd., Taiho Pharmaceutical Co., Ltd. by Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, and VolitionRx Limited.

Market Segmentation & Coverage

This research report categorizes the Colorectal Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Anti-angiogenic Drugs, Chemotherapy Drugs, Immunotherapy Drugs, and Targeted Therapy Drugs.
  • Based on Treatment Type, market is studied across First-Line Treatment, Second-Line Treatment, and Third-Line Treatment and Beyond.
  • Based on Route of Administration, market is studied across Intravenous, Oral, and Subcutaneous.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surging prevalence of colon and rectal cancer worldwide
      • 5.1.1.2. Increase in investments and government funding in development of cancer drugs
      • 5.1.1.3. Rapid adoption of novel medicines
    • 5.1.2. Restraints
      • 5.1.2.1. High cost for developing colon cancer drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing research and development studies for colorectal cancer treatment
      • 5.1.3.2. Proliferation of online pharmacies and telehealth facilities
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of development in the neoadjuvant/adjuvant pipeline agents for the treatment of high risk colorectal cancer
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Colorectal Cancer Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Anti-angiogenic Drugs
  • 6.3. Chemotherapy Drugs
  • 6.4. Immunotherapy Drugs
  • 6.5. Targeted Therapy Drugs

7. Colorectal Cancer Drugs Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. First-Line Treatment
  • 7.3. Second-Line Treatment
  • 7.4. Third-Line Treatment and Beyond

8. Colorectal Cancer Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral
  • 8.4. Subcutaneous

9. Colorectal Cancer Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacy
  • 9.3. Online Pharmacy
  • 9.4. Retail Pharmacy

10. Americas Colorectal Cancer Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Colorectal Cancer Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Colorectal Cancer Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Takeda to license potential treatment for colorectal cancer
    • 13.3.2. FDA grants accelerated approval to tucatinib with trastuzumab for colorectal cancer
    • 13.3.3. Carina Biotech raises funds for colorectal cancer research
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Accord Healthcare Limited by Intas Pharmaceuticals Ltd.
  • 2. Amgen Inc.
  • 3. Amneal Pharmaceuticals, Inc.
  • 4. Apotex Inc.
  • 5. Bayer AG
  • 6. Bristol-Myers Squibb Company
  • 7. Eisai Co., Ltd.
  • 8. Eli Lilly and Company
  • 9. F. Hoffmann-La Roche Ltd
  • 10. GlaxoSmithKline PLC
  • 11. HUTCHMED (China) Limited
  • 12. Lupin Limited
  • 13. Mallinckrodt Pharmaceuticals
  • 14. Manus Aktteva Biopharma LLP
  • 15. Marksans Pharma Ltd.
  • 16. Merck & Co., Inc.
  • 17. Mylan N.V. by Viatris Inc.
  • 18. Novartis AG
  • 19. Pfizer Inc.
  • 20. Regeneron Pharmaceuticals, Inc.
  • 21. Sanofi S.A.
  • 22. Sumitomo Pharma Co., Ltd.
  • 23. Taiho Pharmaceutical Co., Ltd. by Otsuka Pharmaceutical Co., Ltd.
  • 24. Takeda Pharmaceutical Company Limited
  • 25. VolitionRx Limited

LIST OF FIGURES

  • FIGURE 1. COLORECTAL CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. COLORECTAL CANCER DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. COLORECTAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. COLORECTAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. COLORECTAL CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. COLORECTAL CANCER DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ANTI-ANGIOGENIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY FIRST-LINE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SECOND-LINE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY THIRD-LINE TREATMENT AND BEYOND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. COLORECTAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. COLORECTAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023